Search

Merck, known as MSD outside of the United States and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending [...]

Merck, known as MSD outside of the United States and Canada, reported that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending approval [...]

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Eisai R&D Management Co. Ltd. (Tokyo, Japan) has been issued patent number 12083112, according [...]

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventor RUIZ SOTO, Rodrigo R. (Boston, MA, US), filed [...]

2024 SEP 30 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors FAN, [...]

The 'Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028' report has been added to ResearchAndMarkets.com's offering. According to a release, inhibition of the cell surface protein [...]

NextCure announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. [...]

Immutep announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD's (MRK) anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or [...]

PDS Biotechnology announced updated data from the VERSATILE-002 trial evaluating Versamune HPV in combination with KEYTRUDA as a first-line treatment for patients with HPV16-positive recurrent/metastatic head and neck squamous cell [...]

Morgan Stanley raised the firm's price target on IO Biotech to $6 from $4 and keeps an Overweight rating on the shares. Updated Phase 2 data presented at ESMO for [...]

Regeneron Pharmaceuticals announced the presentation of data from its oncology portfolio at the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung [...]

Bristol Myers Squibb announced the presentation of nearly 60 abstracts of company-sponsored studies, investigator-sponsored studies, and collaborations from across its oncology portfolio and pipeline at the European Society for Medical [...]

Immunotherapy company ImmunityBio announced the opening of a clinical trial to study ANKTIVA or nogapendekin alfa inbakicept-pmln, together with the investigational AdHER2DC vaccine or autologous dendritic cells transduced with HER2 [...]

Genentech, a member of the Roche Group, announced that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people [...]

Endometrial cancer is one of the most common malignancies of women, and in developed countries the most common of gyneco-oncological malignancies. Adequate treatment depends on the age of the patient, radiological stage of the disease, histological result of the primary biopsy at diagnosis. Postmenopausal or irregular bleeding is often an early alarming symptom of the disease; thus, it can lead to early diagnosis. Operative treatment should be performed based on the decision of a multidisciplinary tumor board with the results of final histology and operative staging postoperative tumor board can set up the adjuvant treatment plan if necessary. In advanced stage the most common therapeutic method is taxane and platinum-based chemotherapy but, molecular profile of the disease can open other immunotherapeutic opportunities, which can be continued as a maintenance therapy. In case of recurrent disease, the beside the option of chemotherapy immunotherapies could be applied as an individual therapy, after the results of its efficacy in progression-free and overall survival confirmed by multiple studies. In our article we are intending to summarize the recent advances in the treatment of the disease regarding the molecular classification and targeted treatment of endometrial cancer, having a robust impact not only on treatment strategies, but on the staging on the disease as well. [ABSTRACT FROM AUTHOR]

Copyright of Quintessenz Zahnmedizin is the property of Quintessenz Verlags GmbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Merck & Co. has entered into a deal with LaNova Medicines Ltd., a Chinese company, to license an experimental cancer antibody called LM-299. The deal is valued at $588 million upfront, with potential milestone payments of up to $2.7 billion. LM-299 is a bispecific antibody that targets cancer in multiple ways, activating the immune system and blocking proteins that tumors use to grow. Merck's acquisition of this drug reflects its strategic efforts to diversify its portfolio beyond its best-selling cancer drug Keytruda. [Extracted from the article]

A study conducted at University Hospital Schleswig-Holstein in Europe examined the adjuvant use of pembrolizumab for stage III melanoma patients with lymph node involvement. The study utilized the European Melanoma Registry to analyze treatment outcomes, including real-world recurrence-free survival and distant metastasis-free survival. The research provides insights into the real-world application of pembrolizumab as an adjuvant therapy for melanoma in Europe. [Extracted from the article]

BioNTech is paying $800 million upfront to buy Biotheus and secure full rights to a leading prospect in the white-hot PD-L1xVEGF-A bispecific space. [ABSTRACT FROM AUTHOR]

A 56-year-old woman developed myasthenia gravis (MG) while undergoing treatment with pembrolizumab for breast cancer. Despite negative autoantibody tests, clinical assessment confirmed the diagnosis of MG, along with concurrent myocarditis, external ophthalmomyositis, and trapezius muscle myositis. The patient showed improvement with methylprednisolone treatment, and pembrolizumab was discontinued while carboplatin and gemcitabine therapy was resumed. [Extracted from the article]

A recent report from Oregon Health & Science University (OHSU) discusses the findings of a study on adjuvant pembrolizumab in renal-cell carcinoma. The research shows that patients who received adjuvant pembrolizumab after nephrectomy had a significant overall survival benefit compared to those who received a placebo. While the effect size was modest, the study highlights a potential treatment option for high-risk clear-cell renal-cell carcinoma patients. The research has been peer-reviewed and provides valuable insights into immunotherapy for cancer treatment. [Extracted from the article]

The article focuses on the FDA (Food and Drug Administration) approval of pembrolizumab combined with pemetrexed and platinum chemotherapy as a first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM), based on the results from the KEYNOTE-483 trial.

A 72-year-old man with adenosquamous carcinoma of the pancreas (ASCP) experienced lack of efficacy with sotorasib treatment and developed pancreatitis while on pembrolizumab. Initially diagnosed with presumed pancreatic ductal adenocarcinoma (PDAC), he was later diagnosed with ASCP due to the presence of the KRAS G12C mutation. Despite the adverse reactions, he resumed pembrolizumab treatment after his pancreatitis resolved. [Extracted from the article]

A retrospective observational study of 21 patients with salivary gland cancer who were treated with pembrolizumab revealed cases of drug toxicity, including pneumonitis, atrial fibrillation, and worsening psoriasis. The patients experienced these adverse effects during their treatment with pembrolizumab, leading to the discontinuation of the medication in both cases. The study did not provide specific details on the ages, sexes, routes, dosages, durations of treatments, or outcomes of the patients. [Extracted from the article]

A 78-year-old man developed optic neuritis while undergoing treatment with pembrolizumab for metastatic small cell lung cancer. After receiving 11 cycles of pembrolizumab, he experienced cloudy vision and was diagnosed with optic neuritis, which caused bilateral optic disc swelling and peripheral field loss in his left eye. Treatment with steroids led to an improvement in his visual acuity and peripheral defects, although hemianopia persisted. [Extracted from the article]

A man in his 60s developed hypothyroidism and hypophysitis while being treated with pembrolizumab for non-small cell lung cancer. Despite the treatment, he experienced lack of efficacy as his liver metastasis increased, leading to the discontinuation of pembrolizumab therapy. He was subsequently treated with carboplatin and paclitaxel, experiencing side effects such as fatigue and dyspnoea, and was later diagnosed with pembrolizumab-induced hypothyroidism and secondary adrenal insufficiency. After receiving appropriate treatment, he did not experience any recurrence of symptoms and was under follow-up for 11 months without progression of his cancer. [Extracted from the article]

A 43-year-old woman developed chronic rhinosinusitis with nasal polyps (CRSwNP) while undergoing treatment with pembrolizumab for endometrial cancer. Her symptoms included nasal obstruction, rhinorrhea, post-nasal drip, and anosmia, with examination revealing bilateral turbinate hypertrophy and large nasal polyps. The woman's blood eosinophil count increased during pembrolizumab treatment, and CRSwNP secondary to pembrolizumab was confirmed. Surgical intervention was recommended, but the woman declined due to her ongoing oncologic treatment. [Extracted from the article]

The article in Reactions Weekly describes three case reports of patients, two women and one man aged 60-62, who developed immune-mediated hepatitis while undergoing treatment with atezolizumab or pembrolizumab for small cell lung cancer or lung adenocarcinoma. The patients experienced varying degrees of hepatitis, with one woman developing grade 3 hepatitis and the other woman and man developing grade 4 and grade 3 hepatitis, respectively. Treatment for the immune-mediated hepatitis included methylprednisolone and prednisone. [Extracted from the article]

The article in Reactions Weekly describes four cases of treatment failure and lack of efficacy in patients with metastatic lung adenocarcinoma and neurofibromin-1 (NF-1) gene mutations. Patients aged between 62-80 years received various treatments including bevacizumab, carboplatin, durvalumab, gemcitabine, paclitaxel, pembrolizumab, pemetrexed, and trametinib. Despite different treatment regimens, all patients experienced disease progression and ultimately died within three months of trametinib initiation. The cases highlight the challenges in managing metastatic lung adenocarcinoma with NF-1 gene mutations and the need for further research in this area. [Extracted from the article]

A 56-year-old woman with metastatic lung adenocarcinoma showed lack of efficacy to multiple chemotherapy treatments, including carboplatin, pemetrexed, pembrolizumab, docetaxel, ramucirumab, and gemcitabine. Despite receiving various lines of chemotherapy between 2019 and 2022, she experienced disease progression in all sites. Further investigations revealed she had metastatic lung adenocarcinoma with CD47-MET fusion, leading to the initiation of off-label capmatinib treatment, which resulted in a complete metabolic response in all active disease sites without adverse events over 18 months. [Extracted from the article]

Former Seagen Inc. CEO David Epstein has launched Ottimo Pharma, a biotech company focusing on a two-pronged approach to combat various cancers. Ottimo's experimental drug, jankistomig, targets the PD-1 protein and VEGF, aiming to unleash an immune system attack and inhibit tumor growth. The company plans to begin clinical trials in late 2025 and is currently in a fundraising round to support early-stage trials. Ottimo aims to demonstrate the drug's efficacy across different cancer types and attract interest from larger pharmaceutical companies for potential acquisition. [Extracted from the article]

A 52-year-old woman developed myocarditis while undergoing treatment with pembrolizumab, belzutifan, and lenvatinib for metastatic renal cell carcinoma. The woman had previously received debulking surgery and other treatments for her condition. Cardiac magnetic resonance and endomyocardial biopsy confirmed the diagnosis of myocarditis as a result of the treatment regimen. [Extracted from the article]

A 46-year-old woman with metaplastic carcinoma of the breast experienced lack of efficacy during treatment with cyclophosphamide, epirubicin, and paclitaxel, followed by pneumonia while on pembrolizumab, gemcitabine, and carboplatin. Despite undergoing radical surgery and chemotherapy, she developed multiple lung metastases, prompting a change in treatment. The patient was diagnosed with drug-induced pneumonia and received methylprednisolone before discontinuing the therapy. Subsequent genetic testing revealed specific variants, and she continued with a different treatment regimen. [Extracted from the article]

A 69-year-old man with Merkel cell carcinoma (MCC) stage IIIA experienced lack of efficacy during treatment with pembrolizumab. Despite developing leptomeningeal disease (LMD) involving cauda equina and tumour cells in CSF, imaging did not show any recurrence aside from LMD, indicating lack of efficacy with pembrolizumab. Subsequent treatment with nivolumab and ipilimumab resulted in stable LMD and systemic tumour clearance, with the patient continuing on maintenance therapy with nivolumab alone. [Extracted from the article]

A retrospective study involving 20 patients between January 2018 and December 2019 reported a case of a patient with metastatic non-small cell lung cancer who developed grade III pneumonitis while being treated with pembrolizumab. The patient received IV pembrolizumab infusion but had to stop treatment due to the pneumonitis, and was subsequently started on corticosteroid therapy. The specific details of the patient's age, sex, duration of treatment to reaction onset, and outcome were not provided in the report. [Extracted from the article]

A 73-year-old woman developed acquired drug resistance while undergoing treatment with carboplatin, pemetrexed, and pembrolizumab for stage IVA advanced lung adenocarcinoma. Despite initial shrinkage of the tumor, the disease progressed after 11 months of treatment. Subsequent NGS testing revealed the presence of a KANK1: ALK fusion, leading to a change in treatment to alectinib, which resulted in a rapid clinical response. [Extracted from the article]

This article from Reactions Weekly discusses a case report of a 62-year-old woman with metastatic translocated renal cell carcinoma who showed lack of efficacy during treatment with axitinib and pembrolizumab. Despite initially showing a partial response, she later experienced progressive metastatic disease, indicating the treatment was not effective. The patient was then switched to lenvatinib while continuing pembrolizumab, resulting in stable disease at the 12-month follow-up. [Extracted from the article]

A 53-year-old woman developed bilateral optic neuritis while undergoing therapy for left vulvar carcinoma with pembrolizumab. She also experienced multidrug resistance during treatment with carboplatin, paclitaxel, and bevacizumab, and lack of efficacy with dexamethasone and methylprednisolone for optic neuritis. Despite initial vision impairment, her condition improved after treatment with plasma exchange, leading to stable vision on follow-up. [Extracted from the article]

A 58-year-old man developed angioedema while undergoing treatment with pembrolizumab for head and neck squamous cell carcinoma. He experienced swelling of the face and neck, leading to hospitalization. Treatment with methylprednisolone, dexamethasone, famotidine, and diphenhydramine helped improve his condition, and his pembrolizumab therapy was temporarily paused during his admission. [Extracted from the article]

A 68-year-old man with stage 4 oesophageal adenocarcinoma developed pneumonitis while being treated with pembrolizumab. Despite receiving methylprednisolone, immune globulin, and antibiotics for the pneumonitis, he exhibited a lack of efficacy. Unfortunately, his condition deteriorated, and he passed away surrounded by family. The medical interventions were stopped as they were deemed ineffective in improving his condition. [Extracted from the article]

A study presented at the IASLC World Conference on Lung Cancer has shown that ivonescimab has a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with first-line non-small cell lung cancer (NSCLC). The study included 398 patients with untreated locally advanced or metastatic NSCLC who were randomly assigned to receive either ivonescimab or pembrolizumab. The median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab. This research suggests that ivonescimab could be a new first-line treatment option for these patients. [Extracted from the article]

A 72-year-old man with stage IIIb lung adenocarcinoma developed recurrent pneumonitis while being treated with pemetrexed and pembrolizumab. Initially, he experienced dyspnea and hypoxia, leading to hospitalization and a diagnosis of community-acquired pneumonia. However, a chest CT revealed ground glass opacities and bronchiectasis, indicating pembrolizumab-induced pneumonitis. The patient's prednisone dose was increased and tapered over two months, resulting in improvement. Pembrolizumab was discontinued, and the patient continued chemotherapy with pemetrexed and carboplatin. However, three months later, he experienced a recurrence of symptoms, which was attributed to pemetrexed-induced recurrent pneumonitis. High-dose prednisone was restarted, leading to improvement and eventual discharge. [Extracted from the article]

A 42-year-old woman developed pulmonary toxicity in the form of cavitary pneumonitis with non-caseating granulomatous inflammation after receiving pembrolizumab treatment for diffuse astrocytoma. She presented with pleuritic chest pain, fatigue, dry cough, and mild shortness of breath. CT scans revealed consolidation and cavitary lesions in the right upper lobe of her lungs. The woman was treated with antibiotics and underwent bronchoscopy, which revealed noncaseating granuloma. Pembrolizumab and the antibiotics were discontinued, and the cavitary mass decreased in size after 2-3 months. The pulmonary toxicity was considered a side effect of pembrolizumab. [Extracted from the article]

A case series published in Reactions Weekly describes nine patients (seven women and two men) aged 24-77 years who developed dermatitis or bowel obstruction while being treated with pembrolizumab for deficient mismatch repair colon cancer. All patients had dMMR CC and initially responded well to pembrolizumab, but between 45 and 604 days after starting treatment, they developed bowel obstruction. One patient also experienced grade 1 dermatitis. Eight patients underwent surgical resection, one was managed conservatively, and one patient died due to bowel obstruction. [Extracted from the article]

A 71-year-old man developed immune-related encephalitis while being treated with pembrolizumab for metastatic lung adeno-squamous carcinoma. The man had a history of diabetes, high blood pressure, and other medical conditions. He experienced symptoms such as confusion and inflammation, and was diagnosed with grade 3 immune-related encephalitis. Treatment with corticosteroids led to a quick improvement, and the man was discharged with a plan for tapering the dose. Despite discontinuing pembrolizumab, the man achieved long-term complete remission of his cancer. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA woman [exact age not stated] developed autoimmune encephalitis during treatment with pembrolizumab for lentiginous melanoma [route, dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

In a retrospective study involving 122 elderly patients with non-small cell lung cancer (NSCLC), three patients developed adverse reactions while receiving pembrolizumab treatment. The reactions included rash, anorexia, and pneumonitis. The exact ages and sexes of the patients were not stated, and details regarding the routes, dosages, outcomes, and durations of treatment were also not provided. [Extracted from the article]

This article discusses two case reports of adverse reactions to various drugs used in the treatment of different types of cancer. The first case involves a 62-year-old man who developed drug intolerance during treatment with oxaliplatin for pancreatic cancer and lung injury during treatment with nivolumab and ipilimumab. The second case involves a 51-year-old man who experienced a lack of efficacy with off-label carboplatin, pemetrexed, and pembrolizumab for lung cancer. Both patients had their treatment plans adjusted accordingly. [Extracted from the article]

The fixed-dose combination failed to improve overall survival, extending the wait for a checkpoint inhibitor that moves the needle in the indication. [ABSTRACT FROM AUTHOR]

A 52-year-old man developed immune-mediated colitis (IMC) while being treated with pembrolizumab for lung adenocarcinoma. He also experienced lack of efficacy with vedolizumab, which was being used to treat the IMC. The man presented to the hospital with worsening diarrhea, blood, mucus, and increased inflammatory markers. Proctoscopy confirmed IMC, and he was also diagnosed with a cytomegalovirus infection. Corticosteroids and valganciclovir were administered, but there was no appropriate response. Vedolizumab was then switched to infliximab, and pembrolizumab was discontinued. The patient experienced complete resolution of symptoms after these changes. [Extracted from the article]